Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-09-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle raised funds for cash management, specifically investing in structured deposits and bank wealth management products. It details the amounts, investment terms, risk controls, and approvals by the board and supervisory committee. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is a regulatory disclosure about capital management activities related to fundraising proceeds. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's use of raised funds and cash management activities.
2024-09-06 Chinese
辰欣药业股份有限公司关于2020年限制性股票激励计划首次授予部分第三期解除限售暨股份上市的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about the unlocking and listing of restricted shares under a 2020 restricted stock incentive plan. It includes information about board meetings, approvals, legal opinions, stock quantities, and dates related to the lifting of restrictions on stock and share repurchases due to employee departures. The document is not a financial report, earnings release, or management discussion but rather a formal announcement about stock incentive plan execution and share listing. This fits the category of a Regulatory Filing (RNS) because it is a regulatory announcement about share unlocking and stock incentive plan progress, not a full report or financial statement. The document length and detail confirm it is not a brief report publication announcement or a simple voting result notice. Therefore, the best classification is Regulatory Filings (RNS).
2024-09-03 Chinese
山东国曜琴岛（济南）律师事务所关于辰欣药业股份有限公司2020年限制性股票激励计划回购注销部分限制性股票和首次授予部分第三个解除限售期解除限售条件成就的法律意见书
Regulatory Filings
2024-09-03 Chinese
辰欣药业股份有限公司关于持股5%以上股东集中竞价减持股份时间届满暨未实施减持的结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's initial holdings, the planned reduction through centralized bidding, and the actual results, which indicate no shares were reduced via the planned method during the specified period. It also references related announcements about internal agreement transfers and shareholder equity changes. The document is a formal disclosure of shareholding changes and reduction plan results, typical of a Major Shareholding Notification. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. It is not a report publication announcement or a regulatory filing of a different nature. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-09-02 Chinese
辰欣药业股份有限公司关于2020年限制性股票激励计划首次授予部分第三个限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's 2020 restricted stock incentive plan, specifically about the achievement of conditions for the third lock-up period release of restricted shares. It includes information about board and supervisory meetings, legal opinions, the number of shares involved, and compliance with regulatory requirements. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement about stock incentive plan conditions being met and shares becoming unrestricted. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share incentive plan status and related corporate actions, not a report or presentation. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive regulatory disclosure.
2024-08-27 Chinese
辰欣药业股份有限公司关于2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 辰欣药业股份有限公司 regarding the storage and actual use of raised funds for the half-year period ending June 30, 2024. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, includes detailed financial figures on fundraising, usage, management, and changes in investment projects. The document is lengthy (over 11,000 characters) and contains substantive financial data and analysis about fundraising and capital usage, not just an announcement or certification. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not an Annual Report, Interim Report, or Earnings Release, as it focuses specifically on fundraising and use of proceeds. Therefore, the appropriate classification is CAP with high confidence.
2024-08-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.